| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
17,522 |
16,052 |
$1.20M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
18,436 |
16,499 |
$1.18M |
| 36415 |
Collection of venous blood by venipuncture |
7,120 |
6,626 |
$1.10M |
| 81025 |
|
1,688 |
1,629 |
$203K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,933 |
3,773 |
$180K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,861 |
1,801 |
$120K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,049 |
1,855 |
$114K |
| 81003 |
|
2,799 |
2,300 |
$102K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
907 |
859 |
$99K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
651 |
593 |
$48K |
| 87210 |
|
487 |
413 |
$48K |
| 82043 |
|
681 |
653 |
$47K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
429 |
424 |
$41K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
161 |
158 |
$25K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
503 |
471 |
$23K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
128 |
124 |
$14K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
124 |
112 |
$12K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
104 |
95 |
$11K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
96 |
96 |
$10K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
172 |
167 |
$9K |
| 0002A |
|
242 |
238 |
$7K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
146 |
136 |
$6K |
| 36416 |
|
236 |
185 |
$6K |
| 90686 |
|
2,097 |
2,045 |
$5K |
| 81001 |
|
705 |
621 |
$5K |
| 0001A |
|
287 |
281 |
$5K |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
177 |
173 |
$4K |
| 83655 |
|
142 |
135 |
$4K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,008 |
971 |
$3K |
| 90656 |
|
321 |
318 |
$3K |
| 90670 |
|
1,007 |
974 |
$3K |
| 82570 |
|
714 |
685 |
$2K |
| 80053 |
Comprehensive metabolic panel |
1,768 |
1,689 |
$2K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
12 |
12 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
30 |
29 |
$1K |
| 85610 |
|
24 |
15 |
$1K |
| 0004A |
|
120 |
116 |
$1K |
| 90715 |
|
930 |
887 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
35 |
29 |
$1K |
| G0438 |
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit |
43 |
39 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,558 |
1,452 |
$1K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
42 |
42 |
$840.45 |
| 90633 |
|
422 |
406 |
$753.71 |
| 80061 |
Lipid panel |
2,049 |
1,927 |
$717.38 |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,368 |
1,310 |
$629.24 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
157 |
148 |
$625.26 |
| 92250 |
|
52 |
49 |
$591.51 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
138 |
135 |
$580.27 |
| 90651 |
|
528 |
522 |
$577.29 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
2,673 |
2,596 |
$412.18 |
| 90716 |
|
98 |
96 |
$300.14 |
| 91320 |
|
186 |
184 |
$293.06 |
| Q3014 |
Telehealth originating site facility fee |
45 |
34 |
$287.44 |
| 0054A |
|
121 |
119 |
$277.13 |
| 90682 |
|
599 |
580 |
$267.03 |
| 85027 |
|
1,245 |
1,170 |
$255.45 |
| 90480 |
|
254 |
251 |
$232.36 |
| 90713 |
|
58 |
58 |
$176.49 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
3,908 |
3,807 |
$165.98 |
| 90739 |
|
389 |
378 |
$136.61 |
| 87207 |
|
85 |
82 |
$126.73 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
1,056 |
974 |
$123.41 |
| 92228 |
|
13 |
13 |
$119.82 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
874 |
816 |
$117.65 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,777 |
1,715 |
$95.91 |
| 90677 |
|
492 |
479 |
$93.01 |
| 90698 |
|
416 |
397 |
$80.00 |
| 0124A |
|
167 |
162 |
$69.03 |
| 90619 |
|
82 |
80 |
$68.44 |
| 90647 |
|
33 |
30 |
$34.27 |
| 90734 |
|
50 |
46 |
$20.17 |
| 90744 |
|
301 |
285 |
$20.17 |
| 87899 |
|
72 |
69 |
$0.00 |
| 90461 |
|
865 |
842 |
$0.00 |
| 90685 |
|
29 |
28 |
$0.00 |
| 86480 |
|
258 |
230 |
$0.00 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
480 |
460 |
$0.00 |
| 90681 |
|
83 |
80 |
$0.00 |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
193 |
190 |
$0.00 |
| 90662 |
|
12 |
12 |
$0.00 |
| 90710 |
|
16 |
15 |
$0.00 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
15 |
13 |
$0.00 |
| 86780 |
|
582 |
548 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
171 |
161 |
$0.00 |
| 87340 |
|
403 |
361 |
$0.00 |
| 90697 |
|
156 |
155 |
$0.00 |
| 86803 |
|
529 |
495 |
$0.00 |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
121 |
117 |
$0.00 |
| 90732 |
|
78 |
73 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
29 |
24 |
$0.00 |
| 90680 |
|
45 |
41 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
12 |
12 |
$0.00 |
| 90723 |
|
51 |
47 |
$0.00 |